Ensysce Biosciences Inc（ENSC）の株式分析ENSCEnsysce Biosciences Inc

Ensysce Biosciences, Inc. is a clinical-stage pharmaceutical company. It develops solutions for severe pain relief while reducing the potential for opioid misuse, abuse, and overdose. Its pipeline includes an abuse-resistant opioid prodrug technology, the Trypsin Activated Abuse Protection (TAAP) platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant (MPAR) platform. Its lead product, PF614, is a TAAP extended-release oxycodone and a potential analgesic to treat severe pain. Its second product, PF614-MPAR, is to treat severe pain with the added benefit of oral overdose protection, is a combination product of the TAAP prodrug PF614 with a trypsin inhibitor. Additionally, nafamostat, which is an ingredient in its overdose protection combination products, is also being developed for the intended purpose of treating infection and pulmonary lung diseases. It is also developing novel neuroplastogenic therapies for complex regional pain syndrome. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ensysce Biosciences Inc is a good buy right now due to its recent acquisition of Cy Biopharma and securing $77 million in financing, which has positively impacted its stock price, increasing by 44.83% to $0.52. Additionally, the stock has shown a 58.06% increase over the last 20 days, indicating strong momentum. However, the company has a high risk with a current debt to equity ratio of 0%, suggesting potential financial instability if revenues do not improve.